Galectin-3 Enhances Trastuzumab Resistance by Regulating Cancer Malignancy and Stemness in HER2-positive Breast Cancer Cells

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2022 May 23

PMID 35599381

Authors

Yuqiu Chen

Jiawei Xu

Wang Pan

Xiaofan Xu

Xueping Ma

Yanan Chu

Lu Wang

Shuyun Pang

Yujiao Li

Bingjie Zou

Guohua Zhou

Jun Gu

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to explore the role of galectin-3 in human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells and the potential mechanism.

Methods: Kaplan-Meier (KM)-plot and The Cancer Genome Atlas (TCGA) databases were used to study the role of galectin-3 in the prognosis of HER2-positive breast cancer. The effects of galectin-3 on cell proliferation, migration, invasion, and colony formation ability in HER2-positive breast cancer cells were examined. The relationship between galectin-3 and important components in the HER2 pathways, including HER2, epidermal growth factor receptor (EGFR), protein kinase B (AKT), and phosphatase and tensin homolog (PTEN), was further studied. Lentivirus and CRISPR/Cas9 were used to construct stable cell lines. Cell counting kit-8 (CCK-8) and apoptosis assays were used to study the relationship between galectin-3 and trastuzumab. The effect of galectin-3 on cell stemness was studied by mammosphere formation assay. The effects of galectin-3 on stemness biomarkers and the Notch1 pathway were examined. Tumorigenic models were used to evaluate the effects of galectin-3 on tumorigenesis and the therapeutic effect of trastuzumab in vivo.

Results: HER2-positive breast cancer patients with a high expression level of LGALS3 (the gene encoding galectin-3) messenger RNA (mRNA) showed a poor prognosis. Galectin-3 promoted cancer malignancy through phosphoinositide 3-kinase (PI3K)/AKT signaling pathway activation and upregulated stemness by activating the Notch1 signaling pathway in HER2-positive breast cancer cells. These two factors contributed to the enhancement of trastuzumab resistance in cells. Knockout of LGALS3 had a synergistic therapeutic effect with trastuzumab both in vitro and in vivo.

Conclusions: Galectin-3 may represent a prognostic predictor and therapeutic target for HER2-positive breast cancer.

Citing Articles

Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review.

Rodriguez Y, Koomson A, Perry R Transl Breast Cancer Res. 2025; 6:8.

PMID: 39980815 PMC: 11836739. DOI: 10.21037/tbcr-24-39.

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.

Matoba Y, Zarrella D, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S Br J Cancer. 2024; 130(9):1463-1476.

PMID: 38438589 PMC: 11058234. DOI: 10.1038/s41416-024-02621-x.

Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy.

Liu D, Zhu H, Li C Biomark Res. 2023; 11(1):22.

PMID: 36814341 PMC: 9945697. DOI: 10.1186/s40364-023-00466-9.

Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells.

Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y Thorac Cancer. 2022; 13(13):1961-1973.

PMID: 35599381 PMC: 9250839. DOI: 10.1111/1759-7714.14474.

References

Wong H, Leung R, Kwong A, Chiu J, Liang R, Swanton C . Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. Oncologist. 2011; 16(11):1535-46. PMC: 3233287. DOI: 10.1634/theoncologist.2011-0165. View

Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y . Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thorac Cancer. 2022; 13(13):1961-1973. PMC: 9250839. DOI: 10.1111/1759-7714.14474. View

Matos L, Giglio A, Matsubayashi C, Farah M, Del Giglio A, da Silva Pinhal M . Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012; 7:97. PMC: 3523001. DOI: 10.1186/1746-1596-7-97. View

Kang H, Kim D, Kim S, Cho Y, Jung J, Jang W . Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget. 2016; 7(42):68229-68241. PMC: 5356551. DOI: 10.18632/oncotarget.11920. View

Brouxhon S, Kyrkanides S, Teng X, Raja V, OBanion M, Clarke R . Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways. Clin Cancer Res. 2013; 19(12):3234-46. PMC: 4014632. DOI: 10.1158/1078-0432.CCR-12-2747. View

Li G, Zhao L, Li W, Fan K, Qian W, Hou S . Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget. 2014; 5(18):8317-29. PMC: 4226685. DOI: 10.18632/oncotarget.2135. View

Elizalde P, Cordo Russo R, Chervo M, Schillaci R . ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer. 2016; 23(12):T243-T257. DOI: 10.1530/ERC-16-0360. View

Tanida S, Mori Y, Ishida A, Akita K, Nakada H . Galectin-3 binds to MUC1-N-terminal domain and triggers recruitment of β-catenin in MUC1-expressing mouse 3T3 cells. Biochim Biophys Acta. 2014; 1840(6):1790-7. DOI: 10.1016/j.bbagen.2014.02.008. View

Park Y, Jung H, Choi M, Chang W, Choi Y, Do I . Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br J Cancer. 2013; 110(2):384-91. PMC: 3899777. DOI: 10.1038/bjc.2013.757. View

10.

Nami B, Wang Z . HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance. Cancers (Basel). 2017; 9(5). PMC: 5447950. DOI: 10.3390/cancers9050040. View

11.

Duchnowska R, Sperinde J, Czartoryska-Arlukowicz B, Mysliwiec P, Winslow J, Radecka B . Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab. Oncotarget. 2017; 8(61):104149-104159. PMC: 5732794. DOI: 10.18632/oncotarget.22027. View

12.

Nangia-Makker P, Wang Y, Raz T, Tait L, Balan V, Hogan V . Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer. 2010; 127(11):2530-41. PMC: 3334857. DOI: 10.1002/ijc.25254. View

13.

Dash P, Minz A, Senapati S . Possible Autocrine Function of Galectin-3 in Pancreatic Stellate Cells. Gastroenterology. 2018; 155(3):933-934. DOI: 10.1053/j.gastro.2018.01.076. View

14.

Abravanel D, Belka G, Pan T, Pant D, Collins M, Sterner C . Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy. J Clin Invest. 2015; 125(6):2484-96. PMC: 4497740. DOI: 10.1172/JCI74883. View

15.

Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen A . Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2010; 29(3):264-71. DOI: 10.1200/JCO.2010.30.8213. View

16.

Mitri Z, Constantine T, ORegan R . The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2013; 2012:743193. PMC: 3539433. DOI: 10.1155/2012/743193. View

17.

Nangia-Makker P, Hogan V, Raz A . Galectin-3 and cancer stemness. Glycobiology. 2018; 28(4):172-181. PMC: 6279147. DOI: 10.1093/glycob/cwy001. View

18.

Hurvitz S, Hu Y, OBrien N, Finn R . Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2012; 39(3):219-29. PMC: 3835685. DOI: 10.1016/j.ctrv.2012.04.008. View

19.

Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona M . Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol. 2019; 139:53-66. DOI: 10.1016/j.critrevonc.2019.05.001. View

20.

Fortuna-Costa A, Gomes A, Kozlowski E, Stelling M, Pavao M . Extracellular galectin-3 in tumor progression and metastasis. Front Oncol. 2014; 4:138. PMC: 4058817. DOI: 10.3389/fonc.2014.00138. View